-
1
-
-
84960948722
-
Treatment of murine leukaemia with X rays and homologous bone marrow. Preliminary communication
-
Barnes D.W.H., Corp M.J., Loutit J.F., et al. Treatment of murine leukaemia with X rays and homologous bone marrow. Preliminary communication. British Medical Journal 2 (1956) 626-627
-
(1956)
British Medical Journal
, vol.2
, pp. 626-627
-
-
Barnes, D.W.H.1
Corp, M.J.2
Loutit, J.F.3
-
2
-
-
44049099424
-
Immunological and histological response following spleen treatment in irradiated mice
-
Mitchel J.S., Holmes B.E., and Smith C.L. (Eds), Oliver and Boyd, Edinburgh
-
Barnes D.W.H., and Loutit J.F. Immunological and histological response following spleen treatment in irradiated mice. In: Mitchel J.S., Holmes B.E., and Smith C.L. (Eds). Progress in radiobiology (1956), Oliver and Boyd, Edinburgh 291
-
(1956)
Progress in radiobiology
, pp. 291
-
-
Barnes, D.W.H.1
Loutit, J.F.2
-
5
-
-
0025100777
-
Graft-versus-leukemia reactions after bone marrow transplantation
-
Horowitz M.M., Gale R.P., Sondel P.M., et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75 (1990) 555-562
-
(1990)
Blood
, vol.75
, pp. 555-562
-
-
Horowitz, M.M.1
Gale, R.P.2
Sondel, P.M.3
-
6
-
-
0023690307
-
Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion
-
Goldman J.M., Gale R.P., Horowitz M.M., et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Annals of Internal Medicine 108 (1988) 806-814
-
(1988)
Annals of Internal Medicine
, vol.108
, pp. 806-814
-
-
Goldman, J.M.1
Gale, R.P.2
Horowitz, M.M.3
-
7
-
-
0023940821
-
Bone marrow transplantation for chronic myeloid leukaemia in first chronic phase, Importance of a graft-versus-leukaemia effect
-
Apperley J.F., Mauro F.R., Goldman J.M., et al. Bone marrow transplantation for chronic myeloid leukaemia in first chronic phase, Importance of a graft-versus-leukaemia effect. British Journal of Haematology 69 (1988) 239-245
-
(1988)
British Journal of Haematology
, vol.69
, pp. 239-245
-
-
Apperley, J.F.1
Mauro, F.R.2
Goldman, J.M.3
-
8
-
-
0026049124
-
T-cell depletion of HLA-identical transplants in leukemia
-
Marmont A., Horowitz M.M., Gale R.P., et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 78 (1991) 2120-2130
-
(1991)
Blood
, vol.78
, pp. 2120-2130
-
-
Marmont, A.1
Horowitz, M.M.2
Gale, R.P.3
-
9
-
-
0018764352
-
Antileukemic effect of graft-versus-host disease in recipients of allogeneic-marrow grafts
-
Weiden P.L., Flournoy N., Thomas E.D., et al. Antileukemic effect of graft-versus-host disease in recipients of allogeneic-marrow grafts. The New England Journal of Medicine 300 (1979) 1068-1073
-
(1979)
The New England Journal of Medicine
, vol.300
, pp. 1068-1073
-
-
Weiden, P.L.1
Flournoy, N.2
Thomas, E.D.3
-
10
-
-
0019861205
-
Antileukemic effect of chronic graft-versus-host disease. Contribution to improved survival after allogeneic marrow transplantation
-
Weiden P.L., Sullivan K., Flournoy N., et al. Antileukemic effect of chronic graft-versus-host disease. Contribution to improved survival after allogeneic marrow transplantation. The New England Journal of Medicine 304 (1981) 1529-1533
-
(1981)
The New England Journal of Medicine
, vol.304
, pp. 1529-1533
-
-
Weiden, P.L.1
Sullivan, K.2
Flournoy, N.3
-
11
-
-
44049104351
-
Evidence for a graft versus leukemia effect in clinical bone marrow transplantation
-
Horowitz M.M. Evidence for a graft versus leukemia effect in clinical bone marrow transplantation. Experimental Hematology 16 (1988) 547
-
(1988)
Experimental Hematology
, vol.16
, pp. 547
-
-
Horowitz, M.M.1
-
12
-
-
0018126513
-
Remission of relapsed leukaemia during a graft-versus-host reaction. A 'graft-versus-leukaemia reaction' in man?
-
Odom L.F., August C.S., Githens J.H., et al. Remission of relapsed leukaemia during a graft-versus-host reaction. A 'graft-versus-leukaemia reaction' in man?. The Lancet 2 (1978) 537-540
-
(1978)
The Lancet
, vol.2
, pp. 537-540
-
-
Odom, L.F.1
August, C.S.2
Githens, J.H.3
-
13
-
-
0025329042
-
Durable complete remission of acute nonlymphocytic leukemia associated with discontinuation of immunosuppression following relapse after allogeneic bone marrow transplantation. A case report of a probable graft-versus-leukemia effect
-
Higano C.S., Brixey M., Bryant E.M., et al. Durable complete remission of acute nonlymphocytic leukemia associated with discontinuation of immunosuppression following relapse after allogeneic bone marrow transplantation. A case report of a probable graft-versus-leukemia effect. Transfusion 50 (1990) 175-177
-
(1990)
Transfusion
, vol.50
, pp. 175-177
-
-
Higano, C.S.1
Brixey, M.2
Bryant, E.M.3
-
14
-
-
0026731551
-
Hematologic relapse of chronic myelogenous leukemia following allogeneic bone marrow transplantation. Apparent graft-versus-leukemia effect following abrupt discontinuation of immunosuppression
-
Collins R.H., Rogers Z.R., Bennett M., et al. Hematologic relapse of chronic myelogenous leukemia following allogeneic bone marrow transplantation. Apparent graft-versus-leukemia effect following abrupt discontinuation of immunosuppression. Bone Marrow Transplantation 10 (1992) 391-395
-
(1992)
Bone Marrow Transplantation
, vol.10
, pp. 391-395
-
-
Collins, R.H.1
Rogers, Z.R.2
Bennett, M.3
-
15
-
-
0030642156
-
Graft-versus-leukemia effect of allogeneic bone marrow transplantation and donor mononuclear cell infusions
-
Winter J. (Ed), Kluwer Academic Publishers, Boston
-
Porter D., and Antin J. Graft-versus-leukemia effect of allogeneic bone marrow transplantation and donor mononuclear cell infusions. In: Winter J. (Ed). Blood Stem Cell Transplantation vol. 77 (1997), Kluwer Academic Publishers, Boston 57-85
-
(1997)
Blood Stem Cell Transplantation
, vol.77
, pp. 57-85
-
-
Porter, D.1
Antin, J.2
-
16
-
-
0029100438
-
Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients
-
Kolb H.J., Schattenberg A., Goldman J.M., et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86 (1995) 2041-2050
-
(1995)
Blood
, vol.86
, pp. 2041-2050
-
-
Kolb, H.J.1
Schattenberg, A.2
Goldman, J.M.3
-
17
-
-
2942712161
-
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation
-
[see comments]
-
Collins Jr. R.H., Shpilberg O., Drobyski W.R., et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. [see comments]. Journal of Clinical Oncology 15 (1997) 433-444
-
(1997)
Journal of Clinical Oncology
, vol.15
, pp. 433-444
-
-
Collins Jr., R.H.1
Shpilberg, O.2
Drobyski, W.R.3
-
18
-
-
0022647626
-
Hyperacute graft-v-host disease in patients not given immunosuppression after allogeneic marrow transplantation
-
Sullivan K.M., Deeg H.J., Sanders J., et al. Hyperacute graft-v-host disease in patients not given immunosuppression after allogeneic marrow transplantation. Blood 67 (1986) 1172-1175
-
(1986)
Blood
, vol.67
, pp. 1172-1175
-
-
Sullivan, K.M.1
Deeg, H.J.2
Sanders, J.3
-
19
-
-
0024504726
-
Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms
-
Sullivan K.M., Storb R., Buckner C.D., et al. Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. The New England Journal of Medicine 320 (1989) 828-834
-
(1989)
The New England Journal of Medicine
, vol.320
, pp. 828-834
-
-
Sullivan, K.M.1
Storb, R.2
Buckner, C.D.3
-
20
-
-
34250191090
-
Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy
-
Koh L.P., Chen C.S., Tai B.C., et al. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy. Biology of Blood and Marrow Transplantation 13 (2007) 790-805
-
(2007)
Biology of Blood and Marrow Transplantation
, vol.13
, pp. 790-805
-
-
Koh, L.P.1
Chen, C.S.2
Tai, B.C.3
-
21
-
-
0024566585
-
Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia
-
Sullivan K.M., Weiden P.L., Storb R., et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 73 (1989) 1720-1728
-
(1989)
Blood
, vol.73
, pp. 1720-1728
-
-
Sullivan, K.M.1
Weiden, P.L.2
Storb, R.3
-
22
-
-
0019538222
-
Anti-leukemic effect of graft-versus-host disease contributes to improved survival after allogeneic marrow transplantation
-
Weiden P.L., Flournoy N., Sanders J.E., et al. Anti-leukemic effect of graft-versus-host disease contributes to improved survival after allogeneic marrow transplantation. Transplantation proceedings 13 (1981) 248-251
-
(1981)
Transplantation proceedings
, vol.13
, pp. 248-251
-
-
Weiden, P.L.1
Flournoy, N.2
Sanders, J.E.3
-
23
-
-
1342266375
-
Graft-versus-host disease is associated with a lower relapse incidence after hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia
-
Nordlander A., Mattsson J., Ringden O., et al. Graft-versus-host disease is associated with a lower relapse incidence after hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia. Biology of Blood and Marrow Transplantation 10 (2004) 195-203
-
(2004)
Biology of Blood and Marrow Transplantation
, vol.10
, pp. 195-203
-
-
Nordlander, A.1
Mattsson, J.2
Ringden, O.3
-
24
-
-
0038494593
-
Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation
-
Mielcarek M., Martin P.J., Leisenring W., et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 102 (2003) 756-762
-
(2003)
Blood
, vol.102
, pp. 756-762
-
-
Mielcarek, M.1
Martin, P.J.2
Leisenring, W.3
-
25
-
-
0034665674
-
Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors
-
Nash R.A., Antin J.H., Karanes C., et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 96 (2000) 2062-2068
-
(2000)
Blood
, vol.96
, pp. 2062-2068
-
-
Nash, R.A.1
Antin, J.H.2
Karanes, C.3
-
26
-
-
0032188990
-
Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation
-
Ratanatharathorn V., Nash R.A., Przepiorka D., et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 92 (1998) 2303-2314
-
(1998)
Blood
, vol.92
, pp. 2303-2314
-
-
Ratanatharathorn, V.1
Nash, R.A.2
Przepiorka, D.3
-
27
-
-
33947578933
-
Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation
-
Cutler C., Li S., Ho V.T., et al. Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. Blood 109 (2007) 3108-3114
-
(2007)
Blood
, vol.109
, pp. 3108-3114
-
-
Cutler, C.1
Li, S.2
Ho, V.T.3
-
28
-
-
3342895823
-
Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton
-
Sarbassov D.D., Ali S.M., Kim D.H., et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Current Biology 14 (2004) 1296-1302
-
(2004)
Current Biology
, vol.14
, pp. 1296-1302
-
-
Sarbassov, D.D.1
Ali, S.M.2
Kim, D.H.3
-
29
-
-
22144475453
-
Differential effect of calcineurin inhibitors, anti-CD25 antibodies and rapamycin on the induction of FOXP3 in human T cells
-
Baan C.C., van der Mast B.J., Klepper M., et al. Differential effect of calcineurin inhibitors, anti-CD25 antibodies and rapamycin on the induction of FOXP3 in human T cells. Transplantation 80 (2005) 110-117
-
(2005)
Transplantation
, vol.80
, pp. 110-117
-
-
Baan, C.C.1
van der Mast, B.J.2
Klepper, M.3
-
30
-
-
33745633856
-
Inhibition of CD4+ CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production
-
Zeiser R., Nguyen V.H., Beilhack A., et al. Inhibition of CD4+ CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood 108 (2006) 390-399
-
(2006)
Blood
, vol.108
, pp. 390-399
-
-
Zeiser, R.1
Nguyen, V.H.2
Beilhack, A.3
-
31
-
-
20444373376
-
Rapamycin selectively expands CD4+ CD25+ FoxP3+ regulatory T cells
-
Battaglia M., Stabilini A., and Roncarolo M.G. Rapamycin selectively expands CD4+ CD25+ FoxP3+ regulatory T cells. Blood 105 (2005) 4743-4748
-
(2005)
Blood
, vol.105
, pp. 4743-4748
-
-
Battaglia, M.1
Stabilini, A.2
Roncarolo, M.G.3
-
32
-
-
0032105481
-
Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression
-
Sehgal S.N. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clinical Biochemistry 31 (1998) 335-340
-
(1998)
Clinical Biochemistry
, vol.31
, pp. 335-340
-
-
Sehgal, S.N.1
-
33
-
-
0041941520
-
Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation
-
Antin J.H., Kim H.T., Cutler C., et al. Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation. Blood 102 (2003) 1601-1605
-
(2003)
Blood
, vol.102
, pp. 1601-1605
-
-
Antin, J.H.1
Kim, H.T.2
Cutler, C.3
-
34
-
-
11144354152
-
Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation
-
Cutler C., Kim H.T., Hochberg E., et al. Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. Biology of Blood and Marrow Transplantation 10 (2004) 328-336
-
(2004)
Biology of Blood and Marrow Transplantation
, vol.10
, pp. 328-336
-
-
Cutler, C.1
Kim, H.T.2
Hochberg, E.3
-
35
-
-
0344925935
-
Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT)
-
Champlin R.E., Schmitz N., Horowitz M.M., et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). Blood 95 (2000) 3702-3709
-
(2000)
Blood
, vol.95
, pp. 3702-3709
-
-
Champlin, R.E.1
Schmitz, N.2
Horowitz, M.M.3
-
36
-
-
0035099986
-
Peripheral blood stem cells for allogeneic transplantation: a review
-
Cutler C., and Antin J.H. Peripheral blood stem cells for allogeneic transplantation: a review. Stem Cells 19 (2001) 108-117
-
(2001)
Stem Cells
, vol.19
, pp. 108-117
-
-
Cutler, C.1
Antin, J.H.2
-
37
-
-
0035905908
-
Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers
-
Bensinger W.I., Martin P.J., Storer B., et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. The New England Journal of Medicine 344 (2001) 175-181
-
(2001)
The New England Journal of Medicine
, vol.344
, pp. 175-181
-
-
Bensinger, W.I.1
Martin, P.J.2
Storer, B.3
-
38
-
-
33845478320
-
Long-term outcome of patients given transplants of mobilized blood or bone marrow: a report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation
-
Schmitz N., Eapen M., Horowitz M.M., et al. Long-term outcome of patients given transplants of mobilized blood or bone marrow: a report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. Blood 108 (2006) 4288-4290
-
(2006)
Blood
, vol.108
, pp. 4288-4290
-
-
Schmitz, N.1
Eapen, M.2
Horowitz, M.M.3
-
39
-
-
36048969811
-
Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival
-
Eapen M., Logan B.R., Confer D.L., et al. Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival. Biology of Blood and Marrow Transplantation 13 (2007) 1461-1468
-
(2007)
Biology of Blood and Marrow Transplantation
, vol.13
, pp. 1461-1468
-
-
Eapen, M.1
Logan, B.R.2
Confer, D.L.3
-
40
-
-
39149133203
-
Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival
-
Valcarcel D., Martino R., Caballero D., et al. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. Journal of Clinical Oncology 26 (2008) 577-584
-
(2008)
Journal of Clinical Oncology
, vol.26
, pp. 577-584
-
-
Valcarcel, D.1
Martino, R.2
Caballero, D.3
-
41
-
-
0033971243
-
Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Societe Francaise de Greffe de Moelle
-
Blaise D., Kuentz M., Fortanier C., et al. Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Societe Francaise de Greffe de Moelle. Journal of Clinical Oncology 18 (2000) 537-546
-
(2000)
Journal of Clinical Oncology
, vol.18
, pp. 537-546
-
-
Blaise, D.1
Kuentz, M.2
Fortanier, C.3
-
42
-
-
0032406754
-
A randomised, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies
-
Vigorito A.C., Azevedo W.M., Marques J.F., et al. A randomised, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies. Bone Marrow Transplantation 22 (1998) 1145-1151
-
(1998)
Bone Marrow Transplantation
, vol.22
, pp. 1145-1151
-
-
Vigorito, A.C.1
Azevedo, W.M.2
Marques, J.F.3
-
43
-
-
0032423127
-
Chronic graft-versus-host disease after allogeneic peripheral blood progenitor cell or bone marrow transplantation from matched related donors. A case-control study. Spanish Group of Allo-PBT
-
Solano C., Martinez C., Brunet S., et al. Chronic graft-versus-host disease after allogeneic peripheral blood progenitor cell or bone marrow transplantation from matched related donors. A case-control study. Spanish Group of Allo-PBT. Bone Marrow Transplantation 22 (1998) 1129-1135
-
(1998)
Bone Marrow Transplantation
, vol.22
, pp. 1129-1135
-
-
Solano, C.1
Martinez, C.2
Brunet, S.3
-
44
-
-
0037100280
-
Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial
-
Flowers M.E.D., Parker P.M., Johnston L.J., et al. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. Blood 100 (2002) 415-419
-
(2002)
Blood
, vol.100
, pp. 415-419
-
-
Flowers, M.E.D.1
Parker, P.M.2
Johnston, L.J.3
-
45
-
-
0019448114
-
Interleukin-2 augments natural killer cell activity
-
Henney C.S., Kuribayashi K., Kern D.E., et al. Interleukin-2 augments natural killer cell activity. Nature 291 (1981) 335-338
-
(1981)
Nature
, vol.291
, pp. 335-338
-
-
Henney, C.S.1
Kuribayashi, K.2
Kern, D.E.3
-
47
-
-
0023834370
-
In vitro and in vivo susceptibility of human leukemic cells to lymphokine activated killer activity
-
Fierro M.T., Liao X.S., Lusso P., et al. In vitro and in vivo susceptibility of human leukemic cells to lymphokine activated killer activity. Leukemia 2 (1988) 50-54
-
(1988)
Leukemia
, vol.2
, pp. 50-54
-
-
Fierro, M.T.1
Liao, X.S.2
Lusso, P.3
-
48
-
-
0023907713
-
Cytotoxicity of interleukin-2-activated lymphocytes for autologous normal blood mononuclear cells
-
Oshimi K., Oshimi Y., Saito H., et al. Cytotoxicity of interleukin-2-activated lymphocytes for autologous normal blood mononuclear cells. Journal of Immunological Methods 109 (1988) 161-168
-
(1988)
Journal of Immunological Methods
, vol.109
, pp. 161-168
-
-
Oshimi, K.1
Oshimi, Y.2
Saito, H.3
-
49
-
-
0023581741
-
Inhibition of clonogenic growth of fresh leukemia cells by unstimulated and IL-2 stimulated NK cells of normal donors
-
Lotzova E., Savary C.A., and Herberman R.B. Inhibition of clonogenic growth of fresh leukemia cells by unstimulated and IL-2 stimulated NK cells of normal donors. Leukemia Research 11 (1987) 1059-1066
-
(1987)
Leukemia Research
, vol.11
, pp. 1059-1066
-
-
Lotzova, E.1
Savary, C.A.2
Herberman, R.B.3
-
50
-
-
0026070124
-
Defective lymphokine-activated killer cell generation and activity in acute leukemia patients with active disease
-
Foa R., Fierro M.T., Cesano A., et al. Defective lymphokine-activated killer cell generation and activity in acute leukemia patients with active disease. Blood 78 (1991) 1041-1046
-
(1991)
Blood
, vol.78
, pp. 1041-1046
-
-
Foa, R.1
Fierro, M.T.2
Cesano, A.3
-
51
-
-
0025908320
-
Treatment of acute myeloid leukaemia patients with recombinant interleukin 2: a pilot study
-
Foa R., Meloni G., Tosti S., et al. Treatment of acute myeloid leukaemia patients with recombinant interleukin 2: a pilot study. British Journal of Haematology 77 (1991) 491-496
-
(1991)
British Journal of Haematology
, vol.77
, pp. 491-496
-
-
Foa, R.1
Meloni, G.2
Tosti, S.3
-
52
-
-
0025108711
-
IL-2 activated cell-mediated immunotherapy: control of minimal residual disease in malignant disorders by allogeneic lymphocytes and IL-2
-
Slavin S., Ackerstein A., Kedar E., et al. IL-2 activated cell-mediated immunotherapy: control of minimal residual disease in malignant disorders by allogeneic lymphocytes and IL-2. Bone Marrow Transplantation 1 6 Suppl (1990) 86-90
-
(1990)
Bone Marrow Transplantation
, vol.1
, Issue.6 SUPPL
, pp. 86-90
-
-
Slavin, S.1
Ackerstein, A.2
Kedar, E.3
-
53
-
-
0026499915
-
Use of recombinant human interleukin-2 in conjunction with bone marrow transplantation as a model for control of minimal residual disease in malignant hematological disorders: I. Treatment of murine leukemia in conjunction with allogeneic bone marrow transplantation and IL-2-activated cell-mediated immunotherapy
-
Weiss L., Reich S., and Slavin S. Use of recombinant human interleukin-2 in conjunction with bone marrow transplantation as a model for control of minimal residual disease in malignant hematological disorders: I. Treatment of murine leukemia in conjunction with allogeneic bone marrow transplantation and IL-2-activated cell-mediated immunotherapy. Cancer Investigation 10 (1992) 19-26
-
(1992)
Cancer Investigation
, vol.10
, pp. 19-26
-
-
Weiss, L.1
Reich, S.2
Slavin, S.3
-
54
-
-
0026554039
-
Continuous intravenous infusion of high-dose recombinant interleukin-2 for acute myeloid leukaemia - a phase II study
-
Lim S.H., Newland A.C., Kelsey S., et al. Continuous intravenous infusion of high-dose recombinant interleukin-2 for acute myeloid leukaemia - a phase II study. Cancer Immunology Immunotherapy 34 (1992) 337-342
-
(1992)
Cancer Immunology Immunotherapy
, vol.34
, pp. 337-342
-
-
Lim, S.H.1
Newland, A.C.2
Kelsey, S.3
-
55
-
-
0028145247
-
Interleukin-2 may induce prolonged remissions in advanced acute myelogenous leukemia
-
Meloni G., Foa R., Vignetti M., et al. Interleukin-2 may induce prolonged remissions in advanced acute myelogenous leukemia. Blood 84 (1994) 2158-2163
-
(1994)
Blood
, vol.84
, pp. 2158-2163
-
-
Meloni, G.1
Foa, R.2
Vignetti, M.3
-
56
-
-
0025615912
-
Recombinant interleukin 2 for acute myeloid leukaemia in first complete remission: a pilot study
-
Macdonald D., Jiang Y.Z., Gordon A.A., et al. Recombinant interleukin 2 for acute myeloid leukaemia in first complete remission: a pilot study. Leukemia Research 14 (1990) 967-973
-
(1990)
Leukemia Research
, vol.14
, pp. 967-973
-
-
Macdonald, D.1
Jiang, Y.Z.2
Gordon, A.A.3
-
57
-
-
0026512503
-
Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation
-
Soiffer R.J., Murray C., Cochran K., et al. Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation. Blood 79 (1992) 517-526
-
(1992)
Blood
, vol.79
, pp. 517-526
-
-
Soiffer, R.J.1
Murray, C.2
Cochran, K.3
-
58
-
-
6444245790
-
The use of a sequential high dose recombinant interleukin 2 regimen after autologous bone marrow transplantation does not improve the disease free survival of patients with acute leukemia transplanted in first complete remission
-
Blaise D., Attal M., Pico J.L., et al. The use of a sequential high dose recombinant interleukin 2 regimen after autologous bone marrow transplantation does not improve the disease free survival of patients with acute leukemia transplanted in first complete remission. Leukemia & Lymphoma 25 (1997) 469-478
-
(1997)
Leukemia & Lymphoma
, vol.25
, pp. 469-478
-
-
Blaise, D.1
Attal, M.2
Pico, J.L.3
-
59
-
-
0026492347
-
Immunotherapy of minimal residual disease in conjunction with autologous and allogeneic bone marrow transplantation (BMT)
-
Slavin S., Or R., Kapelushnik Y., et al. Immunotherapy of minimal residual disease in conjunction with autologous and allogeneic bone marrow transplantation (BMT). Leukemia 4 6 Suppl (1992) 164-166
-
(1992)
Leukemia
, vol.4
, Issue.6 SUPPL
, pp. 164-166
-
-
Slavin, S.1
Or, R.2
Kapelushnik, Y.3
-
60
-
-
0028332772
-
Effect of low-dose interleukin-2 on disease relapse after T-cell-depleted allogeneic bone marrow transplantation
-
Soiffer R.J., Murray C., Gonin R., et al. Effect of low-dose interleukin-2 on disease relapse after T-cell-depleted allogeneic bone marrow transplantation. Blood 84 (1994) 964-971
-
(1994)
Blood
, vol.84
, pp. 964-971
-
-
Soiffer, R.J.1
Murray, C.2
Gonin, R.3
-
61
-
-
27144500976
-
Reduced frequency of FOXP3+ CD4+ CD25+ regulatory T cells in patients with chronic graft-versus-host disease
-
Zorn E., Kim H.T., Lee S.J., et al. Reduced frequency of FOXP3+ CD4+ CD25+ regulatory T cells in patients with chronic graft-versus-host disease. Blood 106 (2005) 2903-2911
-
(2005)
Blood
, vol.106
, pp. 2903-2911
-
-
Zorn, E.1
Kim, H.T.2
Lee, S.J.3
-
62
-
-
33747801470
-
IL-2 regulates FOXP3 expression in human CD4+ CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo
-
Zorn E., Nelson E.A., Mohseni M., et al. IL-2 regulates FOXP3 expression in human CD4+ CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood 108 (2006) 1571-1579
-
(2006)
Blood
, vol.108
, pp. 1571-1579
-
-
Zorn, E.1
Nelson, E.A.2
Mohseni, M.3
-
63
-
-
0035496939
-
Administration of interleukin-7 after allogeneic bone marrow transplantation improves immune reconstitution without aggravating graft-versus-host disease
-
Alpdogan O., Schmaltz C., Muriglan S.J., et al. Administration of interleukin-7 after allogeneic bone marrow transplantation improves immune reconstitution without aggravating graft-versus-host disease. Blood 98 (2001) 2256-2265
-
(2001)
Blood
, vol.98
, pp. 2256-2265
-
-
Alpdogan, O.1
Schmaltz, C.2
Muriglan, S.J.3
-
64
-
-
0032701975
-
IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation
-
Teshima T., Hill G.R., Pan L., et al. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation. The Journal of Clinical Investigation 104 (1999) 317-325
-
(1999)
The Journal of Clinical Investigation
, vol.104
, pp. 317-325
-
-
Teshima, T.1
Hill, G.R.2
Pan, L.3
-
65
-
-
0032055912
-
Lymphoid reconstitution after autologous PBSC transplantation with FACS-sorted CD34+ hematopoietic progenitors
-
Bomberger C., Singh-Jairam M., Rodey G., et al. Lymphoid reconstitution after autologous PBSC transplantation with FACS-sorted CD34+ hematopoietic progenitors. Blood 91 (1998) 2588-2600
-
(1998)
Blood
, vol.91
, pp. 2588-2600
-
-
Bomberger, C.1
Singh-Jairam, M.2
Rodey, G.3
-
66
-
-
0030709464
-
Interleukin-12 preserves the graft-versus-leukemia effect of allogeneic CD8 T cells while inhibiting CD4-dependent graft-versus-host disease in mice
-
Yang Y.G., Sergio J.J., Pearson D.A., et al. Interleukin-12 preserves the graft-versus-leukemia effect of allogeneic CD8 T cells while inhibiting CD4-dependent graft-versus-host disease in mice. Blood 90 (1997) 4651-4660
-
(1997)
Blood
, vol.90
, pp. 4651-4660
-
-
Yang, Y.G.1
Sergio, J.J.2
Pearson, D.A.3
-
67
-
-
0036838671
-
Interleukin 18 preserves a perforin-dependent graft-versus-leukemia effect after allogeneic bone marrow transplantation
-
Reddy P., Teshima T., Hildebrandt G., et al. Interleukin 18 preserves a perforin-dependent graft-versus-leukemia effect after allogeneic bone marrow transplantation. Blood 100 (2002) 3429-3431
-
(2002)
Blood
, vol.100
, pp. 3429-3431
-
-
Reddy, P.1
Teshima, T.2
Hildebrandt, G.3
-
68
-
-
0029868846
-
Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation
-
Slavin S., Naparstek E., Nagler A., et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 87 (1996) 2195-2204
-
(1996)
Blood
, vol.87
, pp. 2195-2204
-
-
Slavin, S.1
Naparstek, E.2
Nagler, A.3
-
69
-
-
23444449333
-
Induction of graft-vs-host disease as immunotherapy for relapsed chronic myelogenous leukemia
-
Porter D.L., Roth M.S., McGarigle C., et al. Induction of graft-vs-host disease as immunotherapy for relapsed chronic myelogenous leukemia. The New England Journal of Medicine 330 (1994) 100-106
-
(1994)
The New England Journal of Medicine
, vol.330
, pp. 100-106
-
-
Porter, D.L.1
Roth, M.S.2
McGarigle, C.3
-
70
-
-
0038364158
-
Factors predicting response and graft-versus-host disease after donor lymphocyte infusions: a study on 593 infusions
-
Raiola A.M., Van Lint M.T., Valbonesi M., et al. Factors predicting response and graft-versus-host disease after donor lymphocyte infusions: a study on 593 infusions. Bone Marrow Transplantation 31 (2003) 687-693
-
(2003)
Bone Marrow Transplantation
, vol.31
, pp. 687-693
-
-
Raiola, A.M.1
Van Lint, M.T.2
Valbonesi, M.3
-
71
-
-
0037100284
-
Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose
-
Guglielmi C., Arcese W., Dazzi F., et al. Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose. Blood 100 (2002) 397-405
-
(2002)
Blood
, vol.100
, pp. 397-405
-
-
Guglielmi, C.1
Arcese, W.2
Dazzi, F.3
-
72
-
-
0029092530
-
Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: Separation of graft-versus-leukemia responses from graft-versus-host disease
-
Mackinnon S., Papadapoulos E.B., Carabasi M.H., et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: Separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 86 (1995) 1261-1268
-
(1995)
Blood
, vol.86
, pp. 1261-1268
-
-
Mackinnon, S.1
Papadapoulos, E.B.2
Carabasi, M.H.3
-
73
-
-
0033962014
-
Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia
-
Dazzi F., Szydlo R.M., Craddock C., et al. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood 95 (2000) 67-71
-
(2000)
Blood
, vol.95
, pp. 67-71
-
-
Dazzi, F.1
Szydlo, R.M.2
Craddock, C.3
-
74
-
-
20244374668
-
Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant
-
Alyea E.P., Soiffer R.J., Canning C., et al. Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood 91 (1998) 3671-3680
-
(1998)
Blood
, vol.91
, pp. 3671-3680
-
-
Alyea, E.P.1
Soiffer, R.J.2
Canning, C.3
-
75
-
-
0030815867
-
Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation
-
Lokhorst H.M., Schattenberg A., Cornelissen J.J., et al. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood 90 (1997) 4206-4211
-
(1997)
Blood
, vol.90
, pp. 4206-4211
-
-
Lokhorst, H.M.1
Schattenberg, A.2
Cornelissen, J.J.3
-
76
-
-
0033844816
-
Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome
-
Lokhorst H.M., Schattenberg A., Cornelissen J.J., et al. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. Journal of Clinical Oncology 18 (2000) 3031-3037
-
(2000)
Journal of Clinical Oncology
, vol.18
, pp. 3031-3037
-
-
Lokhorst, H.M.1
Schattenberg, A.2
Cornelissen, J.J.3
-
77
-
-
4243319817
-
CD6 T cell depleted allogeneic bone marrow transplant followed by CD4+ donor lymphocyte infusion for patients with multiple myeloma
-
Alyea E., Schossman R., Canning C., et al. CD6 T cell depleted allogeneic bone marrow transplant followed by CD4+ donor lymphocyte infusion for patients with multiple myeloma. Blood 94 (1999) 609a
-
(1999)
Blood
, vol.94
-
-
Alyea, E.1
Schossman, R.2
Canning, C.3
-
78
-
-
34948866783
-
Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning
-
Kahl C., Storer B.E., Sandmaier B.M., et al. Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 110 (2007) 2744-2748
-
(2007)
Blood
, vol.110
, pp. 2744-2748
-
-
Kahl, C.1
Storer, B.E.2
Sandmaier, B.M.3
-
79
-
-
20144362213
-
Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning
-
Baron F., Maris M.B., Sandmaier B.M., et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Journal of Clinical Oncology 23 (2005) 1993-2003
-
(2005)
Journal of Clinical Oncology
, vol.23
, pp. 1993-2003
-
-
Baron, F.1
Maris, M.B.2
Sandmaier, B.M.3
-
80
-
-
0141475940
-
Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation
-
Dey B.R., McAfee S., Colby C., et al. Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation. Biology of Blood and Marrow Transplantation 9 (2003) 320-329
-
(2003)
Biology of Blood and Marrow Transplantation
, vol.9
, pp. 320-329
-
-
Dey, B.R.1
McAfee, S.2
Colby, C.3
-
81
-
-
0842307308
-
Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses
-
Peggs K.S., Thomson K., Hart D.P., et al. Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. Blood 103 (2004) 1548-1556
-
(2004)
Blood
, vol.103
, pp. 1548-1556
-
-
Peggs, K.S.1
Thomson, K.2
Hart, D.P.3
-
82
-
-
9144234680
-
Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning
-
Bethge W.A., Hegenbart U., Stuart M.J., et al. Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. Blood 103 (2004) 790-795
-
(2004)
Blood
, vol.103
, pp. 790-795
-
-
Bethge, W.A.1
Hegenbart, U.2
Stuart, M.J.3
-
83
-
-
34548544801
-
Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes
-
Peggs K.S., Sureda A., Qian W., et al. Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes. British Journal of Haematology 139 (2007) 70-80
-
(2007)
British Journal of Haematology
, vol.139
, pp. 70-80
-
-
Peggs, K.S.1
Sureda, A.2
Qian, W.3
-
84
-
-
37349000995
-
High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma
-
Bloor A.J., Thomson K., Chowdhry N., et al. High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma. Biology of Blood and Marrow Transplantation 14 (2008) 50-58
-
(2008)
Biology of Blood and Marrow Transplantation
, vol.14
, pp. 50-58
-
-
Bloor, A.J.1
Thomson, K.2
Chowdhry, N.3
-
85
-
-
24944495973
-
Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome
-
Schmid C., Schleuning M., Ledderose G., et al. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. Journal of Clinical Oncology 23 (2005) 5675-5687
-
(2005)
Journal of Clinical Oncology
, vol.23
, pp. 5675-5687
-
-
Schmid, C.1
Schleuning, M.2
Ledderose, G.3
-
86
-
-
0028871935
-
CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation
-
Giralt S., Hester J., Huh Y., et al. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood 86 (1995) 4337-4343
-
(1995)
Blood
, vol.86
, pp. 4337-4343
-
-
Giralt, S.1
Hester, J.2
Huh, Y.3
-
87
-
-
0030843493
-
HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia
-
Bonini C., Ferrari G., Verzeletti S., et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 276 (1997) 1719-1724
-
(1997)
Science
, vol.276
, pp. 1719-1724
-
-
Bonini, C.1
Ferrari, G.2
Verzeletti, S.3
-
88
-
-
44049099161
-
Transfer of the HSV-tK gene into donor peripheral blood lymphocytes for in vivo immunomodulation of donor antitumor immunity after allo- BMT
-
[Meeting abstract]
-
Verzeletti S., Bonini C., Traversari C., et al. Transfer of the HSV-tK gene into donor peripheral blood lymphocytes for in vivo immunomodulation of donor antitumor immunity after allo- BMT. [Meeting abstract]. Gene Therapy 1 (1994) S24
-
(1994)
Gene Therapy
, vol.1
-
-
Verzeletti, S.1
Bonini, C.2
Traversari, C.3
-
89
-
-
2642691791
-
Retroviral vector gene transfer into donor peripheral blood lymphocytes for in vitro selection and in vivo immunomodulation of donor antitumor immunity after allo-BMT
-
[Meeting abstract]
-
Verzeletti S., Bonini C., Traversari C., et al. Retroviral vector gene transfer into donor peripheral blood lymphocytes for in vitro selection and in vivo immunomodulation of donor antitumor immunity after allo-BMT. [Meeting abstract]. Journal of Cellular Biochemistry 21A Suppl (1995) 356
-
(1995)
Journal of Cellular Biochemistry
, vol.21 A
, Issue.SUPPL
, pp. 356
-
-
Verzeletti, S.1
Bonini, C.2
Traversari, C.3
|